L. L. Jung

Phase I and Pharmacologic Study of Intermittently Administered 9-Nitrocamptothecin in Patients with Advanced Solid Tumors

M. Fakih, M. Egorin, D. Trump, 2004, Clinical Cancer Research.

Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?

L. L. Jung, William C. Zamboni, 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes

H. McLeod, S. Marsh, M. Egorin, 2006, Investigational New Drugs.

Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts

M. Egorin, S. Strychor, W. Zamboni, 2005, Clinical Cancer Research.

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

M. Fakih, M. Egorin, D. Trump, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

M. Fakih, M. Egorin, S. Strychor, 2005, Cancer Chemotherapy and Pharmacology.